Download 17th World Conference on Lung Cancer

Media Contact:
Shelley Parnell
Sr. Director, Marketing & Investor Relations
[email protected] or 480.703.9268
VisionGate CEO Alan Nelson, PhD, and CMO Javier Zulueta,MD,
to Present Two Pivotal Papers at the
17th World Conference on Lung Cancer
PHOENIX (November 17, 2016) – VisionGate®, Inc., a biotech company focused on the early detection
and prevention of lung cancer, announced today that VisionGate has been invited to present two pivotal
clinical studies at the International Association for the Study of Lung Cancer’s 17th World Conference on
Lung Cancer in Vienna, Austria on December 5, 2016. VisionGate CEO Alan Nelson, PhD, will present a
paper summarizing a blinded clinical study of the LuCED non-invasive test for the early detection of lung
cancer. VisionGate CMO Javier Zulueta, MD, will present a paper summarizing the initial findings of the
LuCED test in the detection of lung dysplasia, the pre-cancer condition targeted by the company’s drug
Iloprost that has shown promise in a successful Phase II clinical trial. Nelson and Zulueta will present at
the Messe Wien Exhibition & Congress Center beginning at approximately 11 a.m. CET as part of the
session titled “Improvement and Implementation of Lung Cancer Screening”.
The IASLC World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung
cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries
to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical
oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic
research scientists, nurses and allied health professionals and patients.
“We are thrilled to be presenting the encouraging data from our recent blinded trial of LuCED for the early
detection of lung cancer and our recent study on detection of the pre-cancer condition called dysplasia,”
Nelson said. “The World Conference on Lung Cancer is the place to learn about the most cutting-edge
advancements in lung cancer, and we are proud to be part of that important discussion.”
For more information about VisionGate, please visit www.VisionGate3D.com.
###
About VisionGate®
VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously
developed the world’s first and only automated screening test to detect cervical cancer, marketed globally
today as FocalPoint by Becton Dickinson. VisionGate’s proprietary LuCED test is a non-invasive
diagnostic test for early-stage lung cancer, demonstrating exquisite sensitivity and specificity in blinded
clinical studies. This physician-ordered, take-home sputum test is processed on the world’s first
automated 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a
CT scan of individual cells, but using visible light without harmful radiation. Moreover, with the new
exclusive patent license from the University of Colorado for the drug called Iloprost, VisionGate will drive
the therapeutic market for chemoprevention of lung cancer and, ultimately, the eradication of this killer.
With 145 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against the
world’s number one cancer killer.